Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure

Circulation

Volumn 112, Issue 12, 2005, Pages 1743-1747

  Van Der Meer, Peter ^a,b   Lipsic, Erik ^a   Westenbrink, B Daan ^a   Van De Wal, Ruud M A ^a   Schoemaker, Regien G ^a   Vellenga, Edo ^a   Van Veldhuisen, Dirk J ^a   Voors, Adriaan A ^a   Van Gilst, Wiek H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE   (Netherlands)

Author keywords

Anemia; Angiotensin; Heart failure; Hematopoiesis; Peptides

Indexed keywords

ANGIOTENSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; HEMATIN; HEMOGLOBIN; SERASPENIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANEMIA; ARTICLE; BURST FORMING UNIT E; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ERYTHROID PRECURSOR CELL; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOPOIESIS; HUMAN; HUMAN CELL; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

AGED; ANEMIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; GLOMERULAR FILTRATION RATE; GROWTH INHIBITORS; HEART FAILURE, CONGESTIVE; HEMATOPOIESIS; HUMANS; MALE; MYOCARDIAL ISCHEMIA; OLIGOPEPTIDES; PEPTIDYL-DIPEPTIDASE A; REFERENCE VALUES; VENTRICULAR FUNCTION, LEFT;

EID: 25444450031     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.549121     Document Type: Article

References (31)

1. van der Meer P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ. Erythropoietin in cardiovascular diseases. Eur Heart J. 2004;25:285-291.
2. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12065 patients with new-onset heart failure. Circulation. 2003;107: 223-225.
3. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780-1786.
4. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the Prospective Randomized Amlodipine Survival Evaluation (PRAISE). J Am Coll Cardiol. 2003;41:1933-1939.
5. van der Meer P, Voors AA, Lipsic E, Smilde TDJ, van Gilst WH, van Veldhuisen DJ. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol. 2004;44:63-67.
6. Cromie N, Lee C, Struthers AD. Anaemia in chronic heart failure: what is its frequency in the UK and its underlying causes? Heart. 2002;87: 377-378.
7. Witte KK, Desilva R, Chattopadhyay S, Ghosh J, Cleland JG, Clark AL. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J. 2004;147:924-930.
8. Cleland JG, Dargie HJ, Hodsman GP, Ball SG, Robertson JI, Morton JJ, East BW, Robertson I, Murray GD, Gillen G. Captopril in heart failure: a double blind controlled trial. Br Heart J. 1984;52:530-535.
9. Cleland JG, Gillen G, Dargie HJ. The effects of frusemide and angioten-sin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure. Eur Heart J. 1988;9:132-141.
10. Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest. 1997;100:2310-2314.
11. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P, Menard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl- lysyl-proline. J Clin Invest. 1996;97:839-844.
12. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527-1560.
13. van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In't Veld AJ. Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension. 1995;25:22-29.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
15. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203-210.
16. Robertshaw M, Lai KN, Swaminathan R. Prediction of creatinine clearance from plasma creatinine: comparison of five formulae. Br J Clin Pharmacol. 1989;28:275-280.
17. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion deletion polymorphism of the human angiotensin converting enzyme gene (Dcpl) (dipeptidyl carboxypeptidase-1). Nucleic Acids Res. 1992; 20:1433.
18. Glicklich D, Kapoian T, Mian H, Gilman J, Tellis V, Croizat H. Effects of erythropoietin, angiotensin II, and angiotensin-converting enzyme inhibitor on erythroid precursors in patients with posttransplantation erythrocytosis. Transplantation. 1999;68:62-66.
19. Naito M, Kawashima A, Akiba T, Takanashi M, Nihei H. Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients. Am J Nephrol. 2003;23:287-293.
20. Plata R, Cornejo A, Arratia C, Anabaya A, Perna A, Dimitrov BD, Remuzzi G, Ruggenenti P. Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. Lancet. 2002;359:663-666.
21. Yildiz A, Cine N, Akkaya V, Sahin S, Ismailoglu V, Turk S, Bozfakioglu S, Sever MS. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. Transplantation. 2001;72:542-544.
22. Griffing GT, Melby JC. Enalapril (MK-421) and the white cell count and haematocrit. Lancet. 1982;1:1361.
23. Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, Herzog CA. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2005;45:391-399.
24. Chatterjee B, Nydegger UE, Mohacsi P. Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists. Eur J Heart Fail. 2000;2:393-398.
25. Pratt MC, Lewis-Earned NJ, Walker RJ, Bailey RR, Shand BI, Livesey J. Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. Br J Clin Pharmacol. 1992;34: 363-365.
26. Lenfant M, Wdzieczak-Bakala J, Guittet E, Prome JC, Sotty D, Frindel E. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc Natl Acad Sci U S A. 1989;86: 779-782.
27. Rousseau A, Michaud A, Chauvet MT, Lenfant M, Corvol P. The hemo-regulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem. 1995;270:3656-3661.
28. Varagunam M, McCloskey DJ, Sinnott PJ, Raftery MJ, Yaqoob MM. Angiotensin-converting enzyme gene polymorphism and erythropoietin requirement. Perit Dial Int. 2003;23:111-115.
29. Le Meur Y, Lorgeot V, Comte L, Szelag JC, Aldigier JC, Leroux-Robert C, Praloran V. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am J Kidney Dis. 2001;38:510-517.
30. Comte L, Lorgeot V, Volkov L, Allegraud A, Aldigier JC, Praloran V. Effects of the angiotensin-converting enzyme inhibitor enalapril on blood haematopoietic progenitors and acetyl-N-Ser-Asp-Lys-Pro concentrations. Eur J Clin Invest. 1997;27:788-790.
31. Felker GM, Adams KF Jr, Gattis WA, O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol. 2004; 44:959-966.